Literature DB >> 24962281

Conformational restriction: an effective tactic in 'follow-on'-based drug discovery.

Zengjun Fang1, Yu'ning Song, Peng Zhan, Qingzhu Zhang, Xinyong Liu.   

Abstract

The conformational restriction (rigidification) of a flexible ligand has often been a commonly used strategy in drug design, as it can minimize the entropic loss associated with the ligand adopting a preferred conformation for binding, which leads to enhanced potency for a given physiological target, improved selectivity for isoforms and reduced the possibility of drug metabolism. Therefore, the application of conformational restriction strategy is a core aspect of drug discovery and development that is widely practiced by medicinal chemists either deliberately or subliminally. The present review will highlight current representative examples and a brief overview on the rational design of conformationally restricted agents as well as discuss its advantages over the flexible counterparts.

Mesh:

Substances:

Year:  2014        PMID: 24962281     DOI: 10.4155/fmc.14.50

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  22 in total

1.  ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model.

Authors:  Yuzo Iwaki; Akira Ohhata; Shingo Nakatani; Katsuya Hisaichi; Yasuyuki Okabe; Atsushi Hiramatsu; Toshihide Watanabe; Shingo Yamamoto; Taihei Nishiyama; Juta Kobayashi; Yasuo Hirooka; Hideki Moriguchi; Tatsuo Maeda; Makoto Katoh; Yuka Komichi; Hiroto Ota; Naoya Matsumura; Masahiro Okada; Tetsuya Sugiyama; Hiroshi Saga; Akira Imagawa
Journal:  ACS Med Chem Lett       Date:  2020-05-14       Impact factor: 4.345

2.  Rational design of agonists for bitter taste receptor TAS2R14: from modeling to bench and back.

Authors:  Antonella Di Pizio; Lukas A W Waterloo; Regine Brox; Stefan Löber; Dorothee Weikert; Maik Behrens; Peter Gmeiner; Masha Y Niv
Journal:  Cell Mol Life Sci       Date:  2019-06-24       Impact factor: 9.261

3.  Discovery of Small Molecule Ligands for MALAT1 by Tuning an RNA-Binding Scaffold.

Authors:  Anita Donlic; Brittany S Morgan; Jason L Xu; Anqi Liu; Carlos Roble; Amanda E Hargrove
Journal:  Angew Chem Int Ed Engl       Date:  2018-09-10       Impact factor: 15.336

4.  Discovery of a Slow Tight Binding LPA1 Antagonist (ONO-0300302) for the Treatment of Benign Prostatic Hyperplasia.

Authors:  Masahiko Terakado; Hidehiro Suzuki; Kazuya Hashimura; Motoyuki Tanaka; Hideyuki Ueda; Keisuke Hirai; Masaki Asada; Masahiro Ikura; Naoki Matsunaga; Hiroshi Saga; Koji Shinozaki; Naoko Karakawa; Yuka Takada; Masashi Minami; Hiromu Egashira; Yoshihiro Sugiura; Masanori Yamada; Shinji Nakade; Yoshikazu Takaoka
Journal:  ACS Med Chem Lett       Date:  2017-11-20       Impact factor: 4.345

5.  Antibacterial Activity of Metergoline Analogues: Revisiting the Ergot Alkaloid Scaffold for Antibiotic Discovery.

Authors:  Jarrod W Johnson; Michael J Ellis; Zoë A Piquette; Craig MacNair; Lindsey Carfrae; Timsy Bhando; Nikki E Ritchie; Paul Saliba; Eric D Brown; Jakob Magolan
Journal:  ACS Med Chem Lett       Date:  2022-01-21       Impact factor: 4.345

6.  Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression.

Authors:  Rohan Kalyan Rej; Changwei Wang; Jianfeng Lu; Mi Wang; Elyse Petrunak; Kaitlin P Zawacki; Donna McEachern; Chao-Yie Yang; Lu Wang; Ruiting Li; Krishnapriya Chinnaswamy; Bo Wen; Duxin Sun; Jeanne A Stuckey; Yunlong Zhou; Jianyong Chen; Guozhi Tang; Shaomeng Wang
Journal:  J Med Chem       Date:  2021-10-06       Impact factor: 7.446

7.  Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CLpro Main Protease.

Authors:  Barbara Herlah; Andrej Hoivik; Luka Jamšek; Katja Valjavec; Norio Yamamoto; Tyuji Hoshino; Krištof Kranjc; Andrej Perdih
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

Review 8.  Cyclisation strategies for stabilising peptides with irregular conformations.

Authors:  Quynh Ngoc Vu; Reginald Young; Haritha Krishna Sudhakar; Tianyi Gao; Tiancheng Huang; Yaw Sing Tan; Yu Heng Lau
Journal:  RSC Med Chem       Date:  2021-04-28

9.  Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy.

Authors:  Brandt C Huddle; Edward Grimley; Mikhail Chtcherbinine; Cameron D Buchman; Cyrus Takahashi; Bikash Debnath; Stacy C McGonigal; Shuai Mao; Siwei Li; Jeremy Felton; Shu Pan; Bo Wen; Duxin Sun; Nouri Neamati; Ronald J Buckanovich; Thomas D Hurley; Scott D Larsen
Journal:  Eur J Med Chem       Date:  2020-12-03       Impact factor: 6.514

10.  Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer's Disease Treatment through Rigidification Strategy.

Authors:  Cédric Lecoutey; Rémi Legay; Audrey Davis; Jana Sopková-de Oliveira Santos; Patrick Dallemagne; Christophe Rochais
Journal:  Molecules       Date:  2021-04-26       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.